Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Sun, Yifeia; * | Moghekar, Abhayb | Soldan, Anjab | Pettigrew, Corinneb | Greenberg, Barryb | Albert, Marilynb | Wang, Mei-Chengc | and the BIOCARD Research Team
Affiliations: [a] Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY, USA | [b] Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA | [c] Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Correspondence: [*] Correspondence to: Yifei Sun, PhD, 722 West 168th Street, R653, New York, NY 10032, USA. Tel.: +1 212 305 6742; E-mail: [email protected].
Abstract: Background:Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) are altered many years before the onset of clinical symptoms of mild cognitive impairment (MCI). Incorporating clinical symptom onset time into biomarker modeling may enhance our understanding of changes preceding MCI. Objective:Using a new analytical approach, we examined patterns of biomarker change prior to MCI symptom onset among individuals who progressed from normal cognition to MCI, stratified based on the age of symptom onset. We also analyzed biomarker patterns of change among participants who remained cognitively normal, and examined potential modifiers of biomarker trajectories, including demographics and apolipoprotein E (APOE) status. Methods:Analyses included 93 participants who progressed from normal cognition to MCI and 186 participants who remained cognitively normal, over an average follow-up period of 16.2 years. CSF biomarkers, including Aβ42, Aβ40, total tau (t-tau), and phosphorylated tau181 (p-tau181), were measured using the fully automated Lumipulse assays. Results:Among participants who progressed to MCI, Aβ42/Aβ40 decreased, and t-tau and p-tau181 increased. For participants who did not progress to MCI, CSF biomarkers showed relatively stable patterns. In both progressors and non-progressors, APOE4 carriers showed lower Aβ 42/Aβ40 levels (compared to non-carriers) at each point of the mean curves. Among non-progressors, APOE4 carriers had higher levels of p-tau181, p-tau181/(Aβ 42/Aβ40), and t-tau/(Aβ 42/Aβ 40). Additionally, among those who did not progress, female sex was associated with higher levels of t-tau, p-tau181, t-tau/(Aβ 42/Aβ 40), and p-tau181/(Aβ 42/Aβ 40). Conclusions:These findings suggest that this analytic approach may provide additional insights into biomarker changes during early phases of AD.
Keywords: Alzheimer’s disease, amyloid, APOE genotype, biomarkers, cerebrospinal fluid, preclinical AD, tau
DOI: 10.3233/JAD-230807
Journal: Journal of Alzheimer's Disease, vol. 96, no. 1, pp. 287-300, 2023
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]